SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

- SOPHiA GENETICS Logo - ภาพที่ 1

The companies will join forces to advance the use of precision medicine on a global scale

BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.

Headquartered in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory assays, clinical research and software development. It supports an expansive global customer base with its custom applications that help expand and improve the use of precision medicine worldwide.

“We are excited about our collaboration with SOPHiA GENETICS that will aim to take our combined expertise in bioinformatics to help partner organizations across the globe deliver next-generation precision medicine to improve patient care,” said Ramesh Hariharan, CEO and Co-Founder of Strand.

Through the broad-ranging collaboration between SOPHiA GENETICS and Strand, the two companies will use their bioinformatics expertise to expand the ability to accurately analyze key healthcare data and facilitate the use of data-driven decision-making globally. SOPHiA GENETICS will provide support via the decentralized  SOPHiA DDM™  Platform and Strand via its curated variant databases and bioinformatics solutions expertise, and the companies will collaborate on strategic test co-development, among other initiatives, that will look to improve health outcomes in India and globally.

“Strand and SOPHiA GENETICS have a shared vision to improve patient health outcomes through precision medicine,” said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS. “It is imperative that healthcare organizations have the ability to process previously siloed data in a timely manner and receive highly accurate results, which facilitate rapid and effective treatments for cancers and rare diseases. This strategic partnership will further enable innovation.”

The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms. With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on X, LinkedInFacebook, and Instagram.

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on XLinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

About Strand Life Sciences
Strand Life Sciences Private Limited is a genomics-based research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand’s customers include global instrument, diagnostic and pharmaceutical companies. Strand is also a pioneer of genomic testing in India. Strand’s long global bioinformatics track record makes it the most trusted company for genomic diagnostics in the areas of oncology, rare diseases, women’s health, and infectious diseases.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia: Read More